Please login to the form below

Not currently logged in
Email:
Password:

Sparsentan

This page shows the latest Sparsentan news and features for those working in and with pharma, biotech and healthcare.

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets

Now, the company says a phase II trial of sparsentan in focal segmental glomerulosclerosis (FSG), a rare disease characterised by progressive scarring of the kidneys that often leads to kidney failure, ... Sparsentan was brought into Retrophin's pipeline

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics